JANSSEN BIOTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1979-01-01
- Employees
- 10K
- Market Cap
- -
Clinical Trials
13
Active:2
Completed:8
Trial Phases
2 Phases
Phase 2:1
Phase 3:4
Drug Approvals
15
FDA:12
NMPA:3
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 3
4 (80.0%)Phase 2
1 (20.0%)An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis
Active, not recruiting
- Conditions
- Ulcerative Colitis
- First Posted Date
- 2016-06-22
- Last Posted Date
- 2025-11-10
- Lead Sponsor
- Janssen Biotech, Inc.
- Target Recruit Count
- 537
- Registration Number
- NCT02808780
A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)
Phase 3
Terminated
- Conditions
- Arthritis, Rheumatoid
- First Posted Date
- 2013-10-16
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- Janssen Biotech, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT01962974
An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
- Conditions
- Relapsed or Refractory Mantle Cell Lymphoma
- First Posted Date
- 2013-04-16
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Biotech, Inc.
- Registration Number
- NCT01833039
An Observational Study to Evaluate Patient-Reported Experiences of Living With Moderate-to-Severe Plaque Psoriasis
Completed
- Conditions
- Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2012-03-15
- Last Posted Date
- 2015-07-21
- Lead Sponsor
- Janssen Biotech, Inc.
- Target Recruit Count
- 108
- Registration Number
- NCT01555606
A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis
Phase 3
Completed
- Conditions
- Psoriasis
- Interventions
- First Posted Date
- 2012-03-12
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Janssen Biotech, Inc.
- Target Recruit Count
- 478
- Registration Number
- NCT01550744
- Prev
- 1
- 2
- 3
- Next
News
HRSA Approves Eight Drug Companies for 340B Rebate Model Pilot Program Starting January 2025
The Health Resources and Services Administration has approved eight pharmaceutical companies to participate in the 340B Rebate Model Pilot Program, which will begin on January 1, 2025.
Icotrokinra Shows Promising Phase 3 Results for Plaque Psoriasis Treatment
Phase 3 trials show Icotrokinra significantly improved skin clearance in adults and adolescents with moderate to severe plaque psoriasis.
Johnson & Johnson Seeks Approval for Darzalex in High-Risk Smoldering Multiple Myeloma
Johnson & Johnson has submitted applications to the FDA and EMA for Darzalex Faspro to treat high-risk smoldering multiple myeloma.